The U.S. Food and Drug Administration approved a new Pfizer vaccine Monday that’s set to protect infants from respiratory syncytial virus.
The Pfizer vaccine will work through the vaccination of pregnant mothers, who will then pass the antibodies to their unborn fetus.
The approval of the new infant RSV vaccine is significant as RSV remains the leading cause of infant hospitalization in the United States.
Pfizer’s RSV vaccine is likewise already approved and available for adults.
